High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors

Proteasome inhibitors (PIs) are approved backbone treatments in multiple myeloma. More recently, inhibition of proteasome activity with the PI bortezomib has been clinically evaluated as a novel treatment strategy in pediatric acute lymphoblastic leukemia (ALL). However, we lack a marker that could...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lenka Besse, Andrej Besse, Marianne Kraus, Elmer Maurits, Herman S. Overkleeft, Beat Bornhauser, Jean-Pierre Bourquin, Christoph Driessen
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/3cf2946c3b5a4867896f938449af3ded
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!